AU2018200081B2 - Avirulent, immunogenic flavivirus chimeras - Google Patents

Avirulent, immunogenic flavivirus chimeras Download PDF

Info

Publication number
AU2018200081B2
AU2018200081B2 AU2018200081A AU2018200081A AU2018200081B2 AU 2018200081 B2 AU2018200081 B2 AU 2018200081B2 AU 2018200081 A AU2018200081 A AU 2018200081A AU 2018200081 A AU2018200081 A AU 2018200081A AU 2018200081 B2 AU2018200081 B2 AU 2018200081B2
Authority
AU
Australia
Prior art keywords
chimeric viruses
avirulent
chimeric
flavivirus
flaviviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2018200081A
Other versions
AU2018200081A1 (en
Inventor
Natth Bhamarapravati
Siritorn Butrapet
Duane L. Gubler
Claire Y.H. Kinney
Richard M. Kinney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mahidol University
Centers of Disease Control and Prevention CDC
Original Assignee
Mahidol University
GOVERNMENT OF United States, AS REPRESENTED BY SECRETARY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009212794A external-priority patent/AU2009212794B2/en
Priority claimed from AU2012202659A external-priority patent/AU2012202659B8/en
Application filed by Mahidol University, GOVERNMENT OF United States, AS REPRESENTED BY SECRETARY filed Critical Mahidol University
Priority to AU2018200081A priority Critical patent/AU2018200081B2/en
Publication of AU2018200081A1 publication Critical patent/AU2018200081A1/en
Application granted granted Critical
Publication of AU2018200081B2 publication Critical patent/AU2018200081B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. 9845429_ 1 (GHMttr) P47053.AU.5
AU2018200081A 2000-02-16 2018-01-04 Avirulent, immunogenic flavivirus chimeras Expired AU2018200081B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018200081A AU2018200081B2 (en) 2000-02-16 2018-01-04 Avirulent, immunogenic flavivirus chimeras

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60/182,829 2000-02-16
AU2009212794A AU2009212794B2 (en) 2000-02-16 2009-08-25 Avirulent, immunogenic flavivirus chimeras
AU2012202659A AU2012202659B8 (en) 2000-02-16 2012-05-07 Avirulent, immunogenic flavivirus chimeras
AU2015213355A AU2015213355B2 (en) 2000-02-16 2015-08-13 Avirulent, immunogenic flavivirus chimeras
AU2018200081A AU2018200081B2 (en) 2000-02-16 2018-01-04 Avirulent, immunogenic flavivirus chimeras

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2015213355A Division AU2015213355B2 (en) 2000-02-16 2015-08-13 Avirulent, immunogenic flavivirus chimeras

Publications (2)

Publication Number Publication Date
AU2018200081A1 AU2018200081A1 (en) 2018-01-25
AU2018200081B2 true AU2018200081B2 (en) 2019-11-21

Family

ID=54014210

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015213355A Expired AU2015213355B2 (en) 2000-02-16 2015-08-13 Avirulent, immunogenic flavivirus chimeras
AU2018200081A Expired AU2018200081B2 (en) 2000-02-16 2018-01-04 Avirulent, immunogenic flavivirus chimeras

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2015213355A Expired AU2015213355B2 (en) 2000-02-16 2015-08-13 Avirulent, immunogenic flavivirus chimeras

Country Status (1)

Country Link
AU (2) AU2015213355B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716222D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric Flavivirus Vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine

Also Published As

Publication number Publication date
AU2015213355A1 (en) 2015-09-03
AU2015213355B2 (en) 2017-10-05
AU2018200081A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
WO2001060847A3 (en) avirulent, immunogenic flavivirus chimeras
ES2272012T3 (en) FUSION PROTEINS THAT INCLUDE TAT AND / OR NEF PROTEINS OF HIV-1.
JP4918479B2 (en) Immunization against Neisseria meningitidis serogroup Y using proteins
JP4504464B2 (en) Chimeric flavivirus vaccine
EP2173376B1 (en) Multimeric multiepitope influenza vaccines
EP2215269B1 (en) Construct system and uses therefor
HU225169B1 (en) Polynucleotide vaccine formula, particularly for treating bovine respiratory disease
RU2008102654A (en) INACTIVATED CHIMERIC VACCINES AND RELATED METHODS OF APPLICATION
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
JP2008019262A (en) Immunogenic composition for streptococcus agalactiae
JP2023512648A (en) coronavirus vaccine formulation
CA2434000A1 (en) Adjuvant viral particle
Wang et al. M cell DNA vaccination for CTL immunity to HIV
EP3608332B1 (en) Vaccine against human rhinovirus
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
TW200509964A (en) VP1 of foot-and-mouth disease virus
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
US9303070B2 (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2363493A1 (en) Attenuated forms of bovine viral diarrhea virus
Lu et al. Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles
Konno et al. Proteolytic enhancement of human rotavirus infectivity
WO2001055330A3 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
ES2393546T3 (en) Enhanced vaccine formulation by combining a DNA with an antigen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired